Kinase inhibitors: the road ahead

Ferguson, Fleur M., Gray, Nathanael S.·2018·Nature Reviews Drug Discovery
DOI 10.1038/nrd.2018.21

Cites (292)

Items 201–292 of 292

  1. ERK5 kinase activity is dispensable for cellular immune response and proliferation
    Emme C.K. Lin, Christopher M. Amantea, Tyzoon K. Nomanbhoy, Helge Weissig, Junichi Ishiyama, Yi Hu, Shyama Sidique, Bei Li, John W. Kozarich, Jonathan S. Rosenblum · 2016 · Proceedings of the National Academy of Sciences
  2. Plasmodium Kinases As Targets For New-Generation Antimalarials
    Isabelle S. Lucet, Andrew B. Tobin, David H. Drewry, Andrew F. Wilks, Christian Doerig · 2012 · Future Medicinal Chemistry
  3. Dynamic undocking and the quasi-bound state as tools for drug discovery
    Sergio Ruiz Carmona, Peter Schmidtke, Francisco Javier Luque, Lisa M. Baker, Natalia Matassova, Ben J. Davis, Stephen D. Roughley, James B. Murray, Rod E. Hubbard, Xavier Barril · 2016 · Nature Chemistry
  4. Imatinib resistance in CML
    Gisella Volpe, Cristina Panuzzo, Stefano Ulisciani, Daniela Cilloni · 2008 · Cancer Letters
  5. Selective inhibition of the kinase DYRK1A by targeting its folding process
    Isao Kii, Yuto Sumida, Toshiyasu Goto, Rie Sonamoto, Yukiko Okuno, Suguru Yoshida, Tomoe Kato‐Sumida, Yuka Koike, Minako Abe, Yosuke Nonaka et al. · 2016 · Nature Communications
  6. Dual leucine zipper kinase-dependent PERK activation contributes to neuronal degeneration following insult
    Larhammar, Martin, Huntwork-Rodriguez, Sarah, Jiang, Zhiyu, Solanoy, Hilda, Sengupta Ghosh, Arundhati, Wang, Bei, Kaminker, Joshua S, Huang, Kevin, Eastham-Anderson, Jeffrey, Siu, Michael et al. · 2017 · eLife
  7. Toll-Like Receptor (TLR) Response Tolerance: A Key Physiological “ Damage Limitation ” Effect and an Important Potential Opportunity for Therapy
    Andrea Broad, David Jones, John Andrew Kirby · 2006 · Current Medicinal Chemistry
  8. Discovery of Dual Leucine Zipper Kinase (DLK, MAP3K12) Inhibitors with Activity in Neurodegeneration Models
    Snahel D. Patel, Frederick Cohen, Brian J. Dean, Kelly De La Torre, Gauri S. Deshmukh, Anthony A. Estrada, Arundhati Sengupta Ghosh, Paul Gibbons, Amy E. Gustafson, Malcolm P. Huestis et al. · 2014 · Journal of Medicinal Chemistry
  9. Global survey of the immunomodulatory potential of common drugs
    Vladimer, Gregory I, Snijder, Berend, Krall, Nikolaus, Bigenzahn, Johannes W, Huber, Kilian V M, Lardeau, Charles-Hugues, Sanjiv, Kumar, Ringler, Anna, Berglund, Ulrika Warpman, Sabler, Monika et al. · 2017 · Nature Chemical Biology
  10. The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
    Yubing Zhou, Jacson K. Shen, Francis John Hornicek, Quancheng Kan, Zhenfeng Duan · 2016 · Oncotarget
  11. Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials
    Mario Fiore, Stefano Forli, Fabrizio Manetti · 2015 · Journal of Medicinal Chemistry
  12. Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
    Peter M. Fischer · 2016 · Medicinal Research Reviews
  13. Cancer Immunology and Immunotherapy
    Ammar W. Sukari, Misako Nagasaka, Ameer Al‐Hadidi, Lawrence G. Lum · 2016 · Anticancer Research
  14. Protein Degradation via CRL4CRBN Ubiquitin Ligase: Discovery and Structure–Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1
    Joshua D. Hansen, Kevin R. Condroski, Matthew Correa, George W. Muller, Hon‐Wah Man, Alexander L. Ruchelman, Weihong Zhang, Fan Vocanson, Tim Crea, Wei Liu et al. · 2017 · Journal of Medicinal Chemistry
  15. Activity‐Based Protein Profiling: Recent Advances in Probe Development and Applications
    Pengyu Yang, Kai Liu · 2015 · ChemBioChem
  16. MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells
    Lijs Beke, Cenk Kığ, Joannes T. M. Linders, Shannah Boens, An Boeckx, Erika van Heerde, Marc Paradé, An De Bondt, Ilse Van den Wyngaert, Tarig Bashir et al. · 2015 · Bioscience Reports
  17. GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein
    Margaret J. Clark, Chandra Miduturu, Aaron G. Schmidt, Xuling Zhu, Jared Pitts, Jinhua Wang, Supanee Potisopon, Jianming Zhang, Amy Wojciechowski, Justin Jang Hann Chu et al. · 2016 · Cell chemical biology
  18. Life Beyond Kinases: Structure-Based Discovery of Sorafenib as Nanomolar Antagonist of 5-HT Receptors
    Lin, Xingyu, Huang, Xi-Ping, Chen, Gang, Whaley, Ryan, Peng, Shiming, Wang, Yanli, Zhang, Guoliang, Wang, Simon X., Wang, Shaohui, Roth, Bryan L. et al. · 2012 · Journal of Medicinal Chemistry
  19. Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells
    Liv H Johannessen, Thomas B. Sundberg, Daniel J O'Connell, Raivo Kolde, James Berstler, Katelyn Billings, Bernard Khor, Brinton A. Seashore-Ludlow, Anne Fassl, Caitlin N. Russell et al. · 2017 · Nature Chemical Biology
  20. Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity
    Shailesh P. Dudhgaonkar, Sourabh Ranade, Jignesh Nagar et al. · 2016 · The Journal of Immunology
  21. Quantifying the Entropy of Binding for Water Molecules in Protein Cavities by Computing Correlations
    David J. Huggins · 2015 · Biophysical Journal
  22. DYRK1A Kinase Inhibitors with Emphasis on Cancer
    A. Ionescu, F. Dufrasne, Michel Gelbcke, Ivan Jabin, Robert Kiss A, Delphine Lamoral‐Theys · 2012 · Mini-Reviews in Medicinal Chemistry
  23. ERK5 and Cell Proliferation: Nuclear Localization Is What Matters
    Néstor Gómez, Tatiana Erazo, José Miguel Lizcano · 2016 · Frontiers in Cell and Developmental Biology
  24. Angiogenesis Inhibition in Cancer Therapy
    Iris Appelmann, Rüediger Liersch, Torsten Keßler, Rolf Michael Mesters, Wolfgang E. Berdel · 2009 · Recent results in cancer research/Recent Results in Cancer Research
  25. Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1
    Xianming Deng, Qingkai Yang, Nicholas P. Kwiatkowski, Taebo Sim, Ultan McDermott, Jeffrey E. Settleman, Jiing-Dwan Lee, Nathanael S. Gray · 2011 · ACS Medicinal Chemistry Letters
  26. The basal transcription machinery as a target for cancer therapy
    Claudia Villicaña, Grisel Cruz‐Becerra, Mario Zurita · 2014 · Cancer Cell International
  27. Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
    Susan Mary O'Brien, Manish R. Patel, Brad S. Kahl et al. · 2014 · Blood
  28. Neuroprotective Mechanisms Mediated by CDK5 Inhibition
    Gohar Mushtaq, Nigel H. Greig, Firoz Anwar, Fahad Ahmed Al-Abbasi, Mazin Abdulaziz Zamzami, Hasan A. Al-Talhi, Mohammad Amjad Kamal · 2016 · Current Pharmaceutical Design
  29. Protein kinases as antibacterial targets
    Mark J Schreiber, Ivica Reš, Alex Matter · 2009 · Current Opinion in Cell Biology
  30. Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N -(1 H -Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12)
    Snahel D. Patel, Seth F. Harris, Paul Gibbons, Gauri S. Deshmukh, Amy E. Gustafson, Terry Kellar, Han Lin, Xingrong Liu, Yanzhou Liu, Yichin Liu et al. · 2015 · Journal of Medicinal Chemistry
  31. Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90–Kinase Interactions
    Meining Wang, Aijun Shen, Chi Zhang, Zilan Song, Jing Ai, Hong‐Chun Liu, Li‐Ping Sun, Jian Ding, Meiyu Geng, Ao Zhang · 2016 · Journal of Medicinal Chemistry
  32. Computing the Thermodynamic Contributions of Interfacial Water
    Zheng Li, Themis Lazaridis · 2011 · Methods in molecular biology
  33. Sphingosine kinase 1 in viral infections
    Jillian M. Carr, Suresh Mahalingam, Claudine S. Bonder, Stuart Maxwell Pitson · 2012 · Reviews in Medical Virology
  34. Kinase inhibitors in the treatment of immune-mediated disease
    Apostolos Kontzias, Arian D. J. Laurence, Massimo Gadina, John J. O’Shea · 2012 · F1000 Medicine Reports
  35. The CDK-activating kinase Cdk7
    Miriam Merzel Schachter, Robert P. Fisher · 2013 · Cell Cycle
  36. Activated PI 3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature
    Peter Olbrich, Myriam Ricarda Lorenz, Paola Cura Daball et al. · 2016 · Pediatric Allergy and Immunology
  37. Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds
    Gregory J. Crowther, Heidi K. Hillesland, Katelyn R. Keyloun, Molly C. Reid, María José Lafuente-Monasterio, Sonja Ghidelli, Stephen E. Leonard, Panqing He, Jackson C. Jones, Mallory M. Krahn et al. · 2016 · PLoS ONE
  38. Redox‐Based Probes for Protein Tyrosine Phosphatases
    Stephen E. Leonard, F. García, David S. Goodsell, Kate S. Carroll · 2011 · Angewandte Chemie International Edition
  39. Future Therapies of Wet Age-Related Macular Degeneration
    Makoto Ishikawa, Daisuke Jin, Yu Sawada, Sanae Abe, Takeshi Yoshitomi · 2015 · Journal of Ophthalmology
  40. Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design To Minimize Host Kinase Interactions.
    Tiansheng Wang, G. Bemis, B. Hanzelka, H. Zuccola, M. Wynn, C. Moody, J. Green, C. Locher, Ai-Xiang Liu, Hong-Wu Gao et al. · 2017 · ACS Medicinal Chemistry Letters
  41. Targeting LRRK2 in Parkinson’s disease: an update on recent developments
    Sharon L. Chan, Eng‐King Tan · 2017 · Expert Opinion on Therapeutic Targets
  42. Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
    Peter B. Alexander, Xiao‐Fan Wang · 2015 · Frontiers of Medicine
  43. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones
    Xianming Deng, Jonathan M. Elkins, Jinwei Zhang, Qingkai Yang, Tatiana Erazo, Néstor Gómez, Hwan Geun Choi, Jinhua Wang, Nicolas L. Dzamko, Jiing-Dwan Lee et al. · 2013 · European Journal of Medicinal Chemistry
  44. Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation
    William T. McElroy, Zheng Tan, Ginny Dai Ho, Sunil Paliwal, Guoqing Li, W. Michael Seganish, Deen Tulshian, James R. Tata, Thierry O. Fischmann, Christopher Sondey et al. · 2015 · ACS Medicinal Chemistry Letters
  45. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
    Malini Bajpai · 2009 · PubMed
  46. Degradation of Akt using protein-catalyzed capture agents
    Ryan K. Henning, Joseph O. Varghese, Samir Das, Arundhati Nag, Grace Y. Tang, Kevin Tang, Alexander M. Sutherland, James R. Heath · 2016 · Journal of Peptide Science
  47. Metabolically Labile Fumarate Esters Impart Kinetic Selectivity to Irreversible Inhibitors
    Balyn W. Zaro, Landon R. Whitby, Kenneth M. Lum, Benjamin F. Cravatt · 2016 · Journal of the American Chemical Society
  48. Neutralization of Vascular Endothelial Growth Factor Antiangiogenic Isoforms Is More Effective Than Treatment with Proangiogenic Isoforms in Stimulating Vascular Development and Follicle Progression in the Perinatal Rat Ovary1
    Robin A. Artac, Renee M. McFee, Robyn A. Longfellow Smith · 2009 · Biology of Reproduction
  49. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis
    Zhengqiang Bao, Chao Cao, Xinwei Geng, Baoping Tian, Yanping Wu, Chao Zhang, Zhihua Chen, Wen Li, Huahao Shen, Songmin Ying · 2015 · Oncotarget
  50. Chemical Interrogation of the Malaria Kinome
    Emily Rose Derbyshire, Vanessa Zuzarte‐Luís, Andreia D. Magalhães, Nobutaka Kato, Paul C. Sanschagrin, Jinhua Wang, Wenjun Zhou, Chandrasekhar V. Miduturu, Ralph Mazitschek, Piotr Sliz A et al. · 2014 · ChemBioChem
  51. Kinobead and Single-Shot LC-MS Profiling Identifies Selective PKD Inhibitors
    Martin G. Golkowski, Rama Subba Rao Vidadala, Chloe K. Lombard, Hyong Won Suh, Dustin J. Maly, Shao‐En Ong · 2017 · Journal of Proteome Research
  52. The Half-Life of c-myc mRNA in Growing and Serum-Stimulated Cells: Influence of the Coding and 3′ Untranslated Regions and Role of Ribosome Translocation
    David J. Herrick, Jeffrey Ross · 1994 · Molecular and Cellular Biology
  53. Novel Phosphoinositide 3-Kinase δ,γ Inhibitor: Potent Anti-Inflammatory Effects and Joint Protection in Models of Rheumatoid Arthritis
    David L. Boyle, Hae‐Rim Kim, Katharyn Topolewski · 2013 · Journal of Pharmacology and Experimental Therapeutics
  54. Role of LRRK2 kinase dysfunction in Parkinson disease
    Azad Kumar, Mark Cookson · 2011 · Expert Reviews in Molecular Medicine
  55. X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor
    Jonathan M. Elkins, Jing Wang, Xianming Deng · 2013 · Journal of Medicinal Chemistry
  56. AXL and acquired resistance to EGFR inhibitors
    Sophie C. Postel-Vinay, Alan Ashworth · 2012 · Nature Genetics
  57. Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration
    Erik L. Meredith, Nello Mainolfi, Stephen H. Poor, Yubin Qiu, Karl Miranda, James J. Powers, Donglei Liu, Fupeng Ma, Catherine Solovay, Chang Rao et al. · 2015 · Journal of Medicinal Chemistry
  58. Ranibizumab Combined With Low-Dose Sorafenib for Exudative Age-Related Macular Degeneration
    Teresa Diago, José S. Pulido, Julian R. Molina · 2008 · Mayo Clinic Proceedings
  59. Ranibizumab Combined With Low-Dose Sorafenib for Exudative Age-Related Macular Degeneration
    Teresa Diago, José S. Pulido, Julian R. Molina · 2008 · Mayo Clinic Proceedings
  60. The Effect of Conformational Flexibility on Binding Free Energy Estimation between Kinases and Their Inhibitors
    M. Araki, N. Kamiya, Miwa Sato, M. Nakatsui, T. Hirokawa, Y. Okuno · 2016 · Journal of Chemical Information and Modeling
  61. Irreversible Enzyme Inhibition Kinetics and Drug–Drug Interactions
    Michael A. Mohutsky, Stephen David Hall · 2014 · Methods in molecular biology
  62. Chemistry-based functional proteomics for drug target deconvolution
    Kui Wang, Tao Yang, Qian Wu, Xia Zhao, Edouard Collins Nice, Canhua Huang · 2012 · Expert Review of Proteomics
  63. An oral androgen receptor PROTAC degrader for prostate cancer.
    Taavi K. Neklesa, Lawrence B. Snyder, Mark Bookbinder et al. · 2017 · Journal of Clinical Oncology
  64. Kinases in synaptic development and neurological diseases
    Lucas L. Baltussen, Flavia Roşianu, Sila K. Ultanir · 2017 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  65. Binding Free-Energy Calculation Is a Powerful Tool for Drug Optimization: Calculation and Measurement of Binding Free Energy for 7-Azaindole Derivatives to Glycogen Synthase Kinase-3β
    Kunihiro Kitamura, Yunoshin Tamura, Tomokazu Ueki · 2014 · Journal of Chemical Information and Modeling
  66. Redox-based probes as tools to monitor oxidized protein tyrosine phosphatases in living cells
    F. García, Kate S. Carroll · 2014 · European Journal of Medicinal Chemistry
  67. 3D-e-Chem-VM: Structural Cheminformatics Research Infrastructure in a Freely Available Virtual Machine
    Ross McGuire, Stefan Verhoeven, Márton Vass, Gerrit Vriend, Iwan J. P. de Esch, Scott J. Lusher, Rob Leurs, Lars Ridder, Albert J. Kooistra, Tina Ritschel et al. · 2017 · Journal of Chemical Information and Modeling
  68. Selective Mycobacterium tuberculosis Shikimate Kinase Inhibitors as Potential Antibacterials
    Sara Gordon, Johayra Simithy, Douglas C. Goodwin · 2015 · Perspectives in Medicinal Chemistry
  69. Taking PI3Kδ and PI3Kγ One Step Ahead: Dual Active PI3Kδ/γ Inhibitors for the Treatment of Immune-Mediated Inflammatory Diseases
    Christian Rommel · 2010 · Current topics in microbiology and immunology
  70. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
    Hong Wu, Qiong Huang, Ziping Qi, Yongfei Chen, Aoli Wang, Cheng Chen, Qianmao Liang, Jing‐Hua Wang, Wensheng Chen, Jin Dong et al. · 2017 · Scientific Reports
  71. Evolution of a New Class of VEGFR-2 Inhibitors from Scaffold Morphing and Redesign
    Nello Mainolfi, Rajeshri G. Karki, Fang Liu · 2016 · ACS Medicinal Chemistry Letters
  72. Propelling Immunotherapy Combinations Into the Clinic.
    Nishan Tchekmedyian, Jhanelle E Gray, Ben Creelan · 2015 · PubMed
  73. Emerging Roles for RIPK1 and RIPK3 in Pathogen-Induced Cell Death and Host Immunity
    Danish Saleh, Alexei Degterev · 2015 · Current topics in microbiology and immunology
  74. Los inhibidores de las proteínas-cinasas en enfermedades autoinmunes e inflamatorias: presente y futuro de nuevas dianas terapéuticas
    Diana Hernández-Flórez, Lara Valor · 2015 · Reumatología Clínica
  75. EML4–ALK Fusions: Propelling Cancer but Creating Exploitable Chaperone Dependence
    Paul Workman, Rob van Montfort · 2014 · Cancer Discovery
  76. Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors
    Fleur M. Ferguson, Jing Ni, Tinghu Zhang · 2016 · ACS Medicinal Chemistry Letters
  77. Could pharmacological curtailment of the RhoA/Rho-kinase pathway reverse the endothelial barrier dysfunction associated with Ebola virus infection?
    Shahram Eisa-Beygi, Xiao‐Yan Wen · 2014 · Antiviral Research
  78. Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET—Letter
    Lorenza Rimassa, Jordi Bruix, Massimo Broggini, Armando Santoro · 2013 · Clinical Cancer Research
  79. Protein-kinase Inhibitors: A New Treatment Pathway for Autoimmune and Inflammatory Diseases?
    Diana Hernández-Flórez, Lara Valor · 2016 · Reumatología Clínica (English Edition)
  80. EGFR Mutant Lung Cancer
    Yixuan Gong, William J. Pao · 2011 · Current topics in microbiology and immunology
  81. New Frontiers in Chemical Biology
    2010 · Royal Society of Chemistry eBooks
  82. Tuning kinase inhibitor residence time
    Megan Cully · 2015 · Nature Reviews Drug Discovery
  83. Conjugate Adaptation of Smooth Pursuit during Monocular Viewing in Strabismic Monkeys with Exotropia
    Seiji Ono, Vallabh E. Das, Michael J. Mustari · 2012 · Investigative Ophthalmology & Visual Science
  84. Lectin Microarray Profiling and Relative Quantification of Glycome Associated With Proteins of Neonatal wt and rd1 Mice Retinae
    Satpal Ahuja · 2013 · Investigative Ophthalmology & Visual Science
  85. New Frontiers in Kinases: Special Issue
    Maurizio Botta · 2014 · ACS Medicinal Chemistry Letters
  86. Abstract 2698: Combination strategies to target super enhancer transcriptional activity by CDK9 and BRD4 inhibition in acute myeloid leukemia
    Brigham L. Bahr, Kyle S. Maughan, Katherine K. Soh · 2015 · Cancer Research
  87. Abstract 1143: Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer
    Michael John Bradley, Jason Marineau, Yoon‐La Choi et al. · 2017 · Cancer Research
  88. Abstract 5637: An oral Androgen Receptor PROTAC degrader for prostate cancer
    Taavi K. Neklesa, Lawrence B. Snyder, Mark Bookbinder et al. · 2017 · Cancer Research
  89. 2038 A Phase I/II Study of Oral Pazopanib, a Receptor Tyrosine Kinase Inhibitor, in Neovascular Age Related Macular Degeneration
    Jason S. Slakter · 2012 · SciVee
  90. New Frontiers in Chemical Biology: Enabling Drug Discovery. Edited by Mark E. Bunnage.
    Joshua A. Kritzer · 2011 · ChemMedChem
  91. Abstract 3025: Discovery of preclinical development candidate inhibitors of the mediator complex-associated kinases CDK8 and CDK19 and evaluation of their therapeutic potential
    Paul Andrew Clarke, Christina Esdar, Aurélie Mallinger, Kai Schiemann, Dennis Waalboer, Simon Crumpler, Christian Rink, Frank Stieber, Michel Calderini, Olajumoke Adeniji-Popoola et al. · 2016 · Cancer Research
  92. Rationale for Treating Wet AMD in Human Using an Oral Pill Consisting of a VEGFR/PDGFR Inhibitor X-82
    Chris Liang, David Brown, Nauman A Chaudhry · 2013 · Investigative Ophthalmology & Visual Science